Direct-to-consumer advertising under the radar: the need for realistic drugs policy in Australia
Authors: Mackenzie; Jordens; Ankeny; McPhee; Kerridge
Source: Internal Medicine Journal, Volume 37, Number 4, April 2007 , pp. 224-228(5)
Direct-to-consumer advertising of prescription medicines (DTCA-PM) is currently banned in Australia. DTCA-PM is thought to increase health-care costs by increasing demand for drugs that are both expensive and potentially harmful. However, DTCA-PM is occurring in Australia despite the current prohibition. We argue that successful regulation of the practice has been undermined as a result of changes brought about by the ongoing communications revolution, the increasing centrality of patient choice in medical decision-making and the impossibility of drawing and maintaining a sharp distinction between information and advertising. The prohibition is further threatened by recent international trade agreements. These factors make DTCA-PM inevitable and legislative and professional bodies need to acknowledge this to create a more effective health-care policy.
Document Type: Research Article
Affiliations: Centre for Values, Ethics and the Law in Medicine
Publication date: April 1, 2007